Marine Omega-3 (N-3) Fatty Acids for Cardiovascular Health: An Update for 2020

Jacqueline K Innes, Philip C Calder, Jacqueline K Innes, Philip C Calder

Abstract

The omega-3 (n-3) fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are found in seafood (especially fatty fish), supplements and concentrated pharmaceutical preparations. Long-term prospective cohort studies consistently demonstrate an association between higher intakes of fish, fatty fish and marine n-3 fatty acids (EPA + DHA) or higher levels of EPA and DHA in the body and lower risk of developing cardiovascular disease (CVD), especially coronary heart disease (CHD) and myocardial infarction (MI), and cardiovascular mortality in the general population. This cardioprotective effect of EPA and DHA is most likely due to the beneficial modulation of a number of known risk factors for CVD, such as blood lipids, blood pressure, heart rate and heart rate variability, platelet aggregation, endothelial function, and inflammation. Evidence for primary prevention of CVD through randomised controlled trials (RCTs) is relatively weak. In high-risk patients, especially in the secondary prevention setting (e.g., post-MI), a number of large RCTs support the use of EPA + DHA (or EPA alone) as confirmed through a recent meta-analysis. This review presents some of the key studies that have investigated EPA and DHA in the primary and secondary prevention of CVD, describes potential mechanisms for their cardioprotective effect, and evaluates the more recently published RCTs in the context of existing scientific literature.

Keywords: cardiovascular disease; coronary heart disease; docosahexaenoic acid; eicosapentaenoic acid; omega-3 polyunsaturated fatty acids.

Conflict of interest statement

J.K.I. has no conflicts of interest to declare. P.C.C. has research funding from BASF AS; acts as an advisor/consultant to BASF AS, DSM, Cargill, Smartfish and Pfizer (now GSK) Consumer Healthcare; and has received reimbursement for travel and/or speaking from Fresenius Kabi, Pfizer (now GSK) Consumer Healthcare and Smartfish.

Figures

Figure 1
Figure 1
Metabolic pathway of conversion of the plant essential n-3 fatty acid, α-linolenic acid (18:3n-3), to eicosapentaenoic acid (20:5n-3) and docosahexaenoic acid (22:6n-3).
Figure 2
Figure 2
Effect of icosapent ethyl compared with placebo on different endpoints in REDUCE-IT [80]. “From New England Journal of Medicine, Bhatt D.L., Steg P.G., Miller M., Brinton E.A., Jacobson T.A., Ketchum S.B., Doyle R.T. Jr., Juliano R.A., Jiao L., Granowitz C., Tardif J.C., Ballantyne C.M.; REDUCE-IT Investigators, Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia, Volume No. 380, Page 11–22, Copyright © (2020) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.”

References

    1. Calder P.C. Very long-chain n-3 fatty acids and human health: Fact, fiction and the future. Proc. Nutr. Soc. 2018;77:52–72. doi: 10.1017/S0029665117003950.
    1. Kaur G., Cameron-Smith D., Garg M., Sinclair A.J. Docosapentaenoic acid (22:5n-3): A review of its biological effects. Prog. Lipid Res. 2011;50:28–34. doi: 10.1016/j.plipres.2010.07.004.
    1. Arterburn L.M., Hall E.B., Oken H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am. J. Clin. Nutr. 2006;83:1467S. doi: 10.1093/ajcn/83.6.1467S.
    1. Baker E.J., Miles E.A., Burdge G.C., Yaqoob P., Calder P.C. Metabolism and functional effects of plant-derived omega-3 fatty acids in humans. Prog. Lipid Res. 2016;64:30–56. doi: 10.1016/j.plipres.2016.07.002.
    1. Meyer B.J., Mann N.J., Lewis J.L., Milligan G.C., Sinclair A.J., Howe P.R. Dietary intakes and food sources of omega-6 and omega-3 polyunsaturated fatty acids. Lipids. 2003;38:391–398. doi: 10.1007/s11745-003-1074-0.
    1. Howe P., Meyer B., Record S., Baghurst K. Dietary intake of long-chain omega-3 polyunsaturated fatty acids: Contribution of meat sources. Nutrition. 2006;22:47–53. doi: 10.1016/j.nut.2005.05.009.
    1. Scientific Advisory Committee on Nutrition/Committee on Toxicity . Advice on Fish Consumption: Benefits and Risks. TSO; London, UK: 2004.
    1. Food and Agricultural Organisation of the United Nations . Fat and Fatty Acids in Human Nutrition: Report of an Expert Consultation. Food and Agricultural Organisation of the United Nations; Rome, Italy: 2010.
    1. European Food Safety Authority Panel on Dietetic Products, Nutrition and Allergies (NDA); Scientific Opinion on the substantiation of health claims related to eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and maintenance. EFSA J. 2010;8:1796. doi: 10.2903/j.efsa.2010.1796.
    1. Kromann N., Green A. Epidemiological studies in the Upernavik district, Greenland. J. Intern. Med. 1980;208:401–406. doi: 10.1111/j.0954-6820.1980.tb01221.x.
    1. Bjerregaard P., Dyerberg J. Mortality from ischaemic heart disease and cerebrovascular disease in Greenland. Int. J. Epidemiol. 1988;17:514–519. doi: 10.1093/ije/17.3.514.
    1. Bang H., Dyerberg J., Hjørne N. The composition of food consumed by Greenland Eskimos. J. Intern. Med. 1976;200:69–73. doi: 10.1111/j.0954-6820.1976.tb08198.x.
    1. Newman W., Middaugh J., Propst M., Rogers D. Atherosclerosis in Alaska Natives and non-Natives. Lancet. 1993;341:1056–1057. doi: 10.1016/0140-6736(93)92413-N.
    1. Yano K., MacLean C.J., Reed D.M., Shimizu Y., Sasaki H., Kodama K., Kato H., Kagan A. A comparison of the 12-year mortality and predictive factors of coronary heart disease among Japanese men in Japan and Hawaii. Am. J. Epidemiol. 1988;127:476–487. doi: 10.1093/oxfordjournals.aje.a114824.
    1. Calder P.C. n-3 Fatty acids and cardiovascular disease: Evidence explained and mechanisms explored. Clin. Sci. 2004;107:1–11. doi: 10.1042/CS20040119.
    1. Hu F., Bronner L., Willett W., Stampfer M., Rexrode K.M., Albert C., Hunter D., Manson J. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA. 2002;287:1815–1821. doi: 10.1001/jama.287.14.1815.
    1. Browning L.M., Walker C.G., Mander A.P., West A.L., Madden J., Gambell J.M., Young S., Wang L., Jebb S.A., Calder P.C. Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish. Am. J. Clin. Nutr. 2012;96:748–758. doi: 10.3945/ajcn.112.041343.
    1. Albert C., Campos H., Stampfer M., Ridker P., Manson J., Willett W., Ma J. Blood levels of long-chain n–3 fatty acids and the risk of sudden death. N. Engl. J. Med. 2002;346:1113–1118. doi: 10.1056/NEJMoa012918.
    1. Zhang Y., Zhuang P., He W., Chen J.N., Wang W.Q., Freedman N.D., Abnet C.C., Wang J.B., Jiao J.J. Association of fish and long-chain omega-3 fatty acids intakes with total and cause-specific mortality: Prospective analysis of 421 309 individuals. J. Intern. Med. 2018;284:399–417. doi: 10.1111/joim.12786.
    1. Djoussé L., Akinkuolie A., Wu J., Ding E., Gaziano J. Fish consumption, omega-3 fatty acids and risk of heart failure: A meta-analysis. Clin. Nutr. 2012;31:846–853. doi: 10.1016/j.clnu.2012.05.010.
    1. Chowdhury R., Warnakula S., Kunutsor S., Crowe F., Ward H., Johnson L., Franco O., Butterworth A., Forouhi N., Thompson S., et al. Association of dietary, circulating, and supplement fatty acids with coronary risk: A systematic review and meta-analysis. Ann. Intern. Med. 2014;160:398–406. doi: 10.7326/M13-1788.
    1. Alexander D.D., Miller P.E., Van Elswyk M.E., Kuratko C.N., Bylsma L.C. A meta-analysis of randomized controlled trials and prospective cohort studies of eicosapentaenoic and docosahexaenoic long-chain omega-3 fatty acids and coronary heart disease risk. Mayo Clin. Proc. 2017;92:15–29. doi: 10.1016/j.mayocp.2016.10.018.
    1. Del Gobbo L.C., Imamura F., Aslibekyan S., Marklund M., Virtanen J.K., Wennberg M., Yakoob M.Y., Chiuve S.E., Dela Cruz L., Frazier-Wood A.C., et al. ω-3 Polyunsaturated fatty acid biomarkers and coronary heart disease: Pooling project of 19 cohort studies. JAMA Intern. Med. 2016;176:1155–1166. doi: 10.1001/jamainternmed.2016.2925.
    1. Harris W.S., Von Schacky C. The Omega-3 Index: A new risk factor for death from coronary heart disease? Prev. Med. 2004;39:212–220. doi: 10.1016/j.ypmed.2004.02.030.
    1. Harris W.S., Del Gobbo L., Tintle N.L. The omega-3 index and relative risk for coronary heart disease mortality: Estimation from 10 cohort studies. Atherosclerosis. 2017;262:51–54. doi: 10.1016/j.atherosclerosis.2017.05.007.
    1. AbuMweis S., Jew S., Tayyem R., Agraib L. Eicosapentaenoic acid and docosahexaenoic acid containing supplements modulate risk factors for cardiovascular disease: A meta-analysis of randomised placebo-control human clinical trials. J. Hum. Nutr. Diet. 2018;31:67–84. doi: 10.1111/jhn.12493.
    1. Miller P.E., Van Elswyk M., Alexander D.D. Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: A meta-analysis of randomized controlled trials. Am. J. Hypertens. 2014;27:885–896. doi: 10.1093/ajh/hpu024.
    1. Mozaffarian D., Geelen A., Brouwer I.A., Geleijnse J.M., Zock P.L., Katan M.B. Effect of fish oil on heart rate in humans: A meta-analysis of randomized controlled trials. Circulation. 2005;112:1945–1952. doi: 10.1161/CIRCULATIONAHA.105.556886.
    1. Xin W., Wei W., Li X. Short-term effects of fish-oil supplementation on heart rate variability in humans: A meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 2013;97:926–935. doi: 10.3945/ajcn.112.049833.
    1. Hidayat K., Yang J., Zhang Z., Chen G.-C., Qin L.-Q., Eggersdorfer M., Zhang W. Effect of omega-3 long-chain polyunsaturated fatty acid supplementation on heart rate: A meta-analysis of randomized controlled trials. Eur. J. Clin. Nutr. 2017 doi: 10.1038/s41430-017-0052-3.
    1. Gao L., Cao J., Mao Q.X., Lu X.X., Zhou X.L., Fan L. Influence of omega-3 polyunsaturated fatty acid-supplementation on platelet aggregation in humans: A meta-analysis of randomized controlled trials. Atherosclerosis. 2013;226:328–334. doi: 10.1016/j.atherosclerosis.2012.10.056.
    1. Xin W., Wei W., Li X. Effect of fish oil supplementation on fasting vascular endothelial function in humans: A meta-analysis of randomized controlled trials. PLoS ONE. 2012;7:e46028. doi: 10.1371/journal.pone.0046028.
    1. Wang Q., Liang X., Wang L., Lu X., Huang J., Cao J., Li H., Gu D. Effect of omega-3 fatty acids supplementation on endothelial function: A meta-analysis of randomized controlled trials. Atherosclerosis. 2012;221:536–543. doi: 10.1016/j.atherosclerosis.2012.01.006.
    1. Pase M.P., Grima N.A., Sarris J. Do long-chain n-3 fatty acids reduce arterial stiffness? A meta-analysis of randomised controlled trials. Br. J. Nutr. 2011;106:974–980. doi: 10.1017/S0007114511002819.
    1. Li K., Huang T., Zheng J., Wu K., Li D. Effect of marine-derived n-3 polyunsaturated fatty acids on C-reactive protein, interleukin-6 and tumor necrosis factor alpha: A meta-analysis. PLoS ONE. 2014;9:e88103. doi: 10.1371/journal.pone.0088103.
    1. Jiang J., Li K., Wang F., Yang B., Fu Y., Zheng J., Li D. Effect of marine-derived n-3 polyunsaturated fatty acids on major eicosanoids: A systematic review and meta-analysis from 18 randomized controlled trials. PLoS ONE. 2016;11:e0147351. doi: 10.1371/journal.pone.0147351.
    1. Innes J.K., Calder P.C. The differential effects of eicosapentaenoic acid and docosahexaenoic acid on cardiometabolic risk factors: A systematic review. Int. J. Mol. Sci. 2018;19:532. doi: 10.3390/ijms19020532.
    1. Grimsgaard S., Bonna K.H., Hansen J.-B., Nordøy A. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. Am. J. Clin. Nutr. 1997;66:649–659. doi: 10.1093/ajcn/66.3.649.
    1. Allaire J., Couture P., Leclerc M., Charest A., Marin J., Lépine M.-C., Talbot D., Tchernof A., Lamarche B. A randomized, crossover, head-to-head comparison of eicosapentaenoic acid and docosahexaenoic acid supplementation to reduce inflammation markers in men and women: The Comparing EPA to DHA (ComparED) Study. Am. J. Clin. Nutr. 2016;104:280–287. doi: 10.3945/ajcn.116.131896.
    1. Woodman R.J., Mori T.A., Burke V., Puddey I.B., Watts G.F., Beilin L.J. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am. J. Clin. Nutr. 2002;76:1007–1015. doi: 10.1093/ajcn/76.5.1007.
    1. Mori T.A., Burke V., Puddey I.B., Watts G.F., O’Neal D.N., Best J.D., Beilin L.J. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am. J. Clin. Nutr. 2000;71:1085–1094. doi: 10.1093/ajcn/71.5.1085.
    1. Grimsgaard S., Bonaa K., Hansen J., Myhre E. Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans. Am. J. Clin. Nutr. 1998;68:52–59. doi: 10.1093/ajcn/68.1.52.
    1. Mori T., Bao D., Burke V., Puddey I., Beilin L. Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension. 1999;34:253–260. doi: 10.1161/01.HYP.34.2.253.
    1. Mori T.A., Watts G.F., Burke V., Hilme E., Puddey I.B., Beilin L.J. Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidaemic, overweight men. Circulation. 2000;102:1264–1269. doi: 10.1161/01.CIR.102.11.1264.
    1. Nestel P., Shige H., Pomeroy S., Cehun M., Abbey M., Raederstorff D. The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. Am. J. Clin. Nutr. 2002;76:326–330. doi: 10.1093/ajcn/76.2.326.
    1. Park Y., Harris W. EPA, but not DHA, decreases mean platelet volume in normal subjects. Lipids. 2002;37:941–946. doi: 10.1007/s11745-006-0984-1.
    1. Woodman R.J., Mori T.A., Burke V., Puddey I.B., Barden A., Watts G.F., Beilin L.J. Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients. Atherosclerosis. 2003;166:85–93. doi: 10.1016/S0021-9150(02)00307-6.
    1. Vors C., Allaire J., Marin J., Lepine M.C., Charest A., Tchernof A., Couture P., Lamarche B. Inflammatory gene expression in whole blood cells after EPA vs. DHA supplementation: Results from the ComparED study. Atherosclerosis. 2017;257:116–122. doi: 10.1016/j.atherosclerosis.2017.01.025.
    1. Mori T.A., Puddey I.B., Burke V., Croft K.D., Dunstan D.W., Rivera J.H., Beilin L.J. Effect of omega 3 fatty acids on oxidative stress in humans: GC-MS measurement of urinary F-2-isoprostane excretion. Redox Rep. 2000;5:45–46. doi: 10.1179/rer.2000.5.1.45.
    1. Mas E., Woodman R.J., Burke V., Puddey I.B., Beilin L.J., Durand T., Mori T.A. The omega-3 fatty acids EPA and DHA decrease plasma F2-isoprostanes: Results from two placebo-controlled interventions. Free Radic. Res. 2010;44:983–990. doi: 10.3109/10715762.2010.492830.
    1. Mori T.A., Woodman R.J., Burke V., Puddey I.B., Croft K.D., Beilin L.J. Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic. Biol. Med. 2003;35:772–781. doi: 10.1016/S0891-5849(03)00407-6.
    1. Yokoyama M., Origasa H., Matsuzaki M., Matsuzawa Y., Saito Y., Ishikawa Y., Oikawa S., Sasaki J., Hishida H., Itakura H., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open- label, blinded endpoint analysis. Lancet. 2007;369:1090–1098. doi: 10.1016/S0140-6736(07)60527-3.
    1. Bowman L., Mafham M., Wallendszus K., Stevens W., Buck G., Barton J., Murphy K., Aung T., Haynes R., Cox J., et al. Effects of n-3 fatty acid supplements in diabetes mellitus. N. Engl. J. Med. 2018;379:1540–1550. doi: 10.1056/NEJMoa1804989.
    1. Manson J.A.E., Cook N.R., Lee I.M., Christen W., Bassuk S.S., Mora S., Gibson H., Albert C.M., Gordon D., Copeland T., et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N. Engl. J. Med. 2019;380:23–32. doi: 10.1056/NEJMoa1811403.
    1. Burr M.L., Gilbert J.F., Holliday R.M., Elwood P.C., Fehily A.M., Rogers S., Sweetnam P.M., Deadman N.M. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and reinfarction trial (DART) Lancet. 1989;344:757–761. doi: 10.1016/S0140-6736(89)90828-3.
    1. The GISSI-Prevenzione Investigators Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Lancet. 1999;354:447–455. doi: 10.1016/S0140-6736(99)07072-5.
    1. Marchioli R., Barzi F., Bomba E., Chieffo C., Di Gregorio D., Di Mascio R., Franzosi M.G., Geraci E., Levantesi G., Maggioni A., et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: Time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002;105:1897–1903. doi: 10.1161/01.CIR.0000014682.14181.F2.
    1. Romagna E. The GISSI-HF Investigators Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1223–1230. doi: 10.1016/S0140-6736(08)61239-8.
    1. Itakura H., Yokoyama M., Matsuzaki M., Saito Y., Origasa H., Ishikawa Y., Oikawa S., Sasaki J., Hishida H., Kita T., et al. Relationships between plasma fatty acid composition and coronary artery disease. J. Atheroscler. Thromb. 2011;18:99–107. doi: 10.5551/jat.5876.
    1. Bucher H.C., Hengstler P., Schindler C., Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: A meta-analysis of randomized controlled trials. Am. J. Med. 2002;112:298–304. doi: 10.1016/S0002-9343(01)01114-7.
    1. Studer M., Briel M., Leimenstoll B., Glass T.R., Bucher H.C. Effect of different antilipidemic agents and diets on mortality: A systematic review. Arch. Intern. Med. 2005;165:725–730. doi: 10.1001/archinte.165.7.725.
    1. Zhao Y.-T., Chen Q., Sun Y.-X., Li X.-B., Zhang P., Xu Y., Guo J.-H. Prevention of sudden cardiac death with omega-3 fatty acids in patients with coronary heart disease: A meta-analysis of randomized controlled trials. Ann. Med. 2009;41:301–310. doi: 10.1080/07853890802698834.
    1. Marik P.E., Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: A systematic review. Clin. Cardiol. 2009;32:365–372. doi: 10.1002/clc.20604.
    1. Rauch B., Schiele R., Schneider S., Diller F., Victor N., Gohlke H., Gottwik M., Steinbeck G., Del Castillo U., Sack R., et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 2010;122:2152–2159. doi: 10.1161/CIRCULATIONAHA.110.948562.
    1. Galan P., Kesse-Guyot E., Czernichow S., Briancon S., Blacher J., Hercberg S. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: A randomised placebo controlled trial. BMJ. 2010;341:c6273. doi: 10.1136/bmj.c6273.
    1. Kromhout D., Giltay E.J., Geleijnse J.M. n–3 Fatty acids and cardiovascular events after myocardial infarction. N. Engl. J. Med. 2010;363:2015–2026. doi: 10.1056/NEJMoa1003603.
    1. Bosch J., Gerstein H., Dagenais G., Diaz R., Dyal L., Jung H., Maggiono A., Probstfield J., Ramachandran A., Riddle M., et al. n–3 Fatty acids and cardiovascular outcomes in patients with dysglycemia (ORIGIN) N. Engl. J. Med. 2012;367:309–318. doi: 10.1056/NEJMoa1203859.
    1. Roncaglioni M., Tombesi M., Avanzini F., Barlera S., Caimi V., Longoni P., Marzona I., Milani V., Silletta M., Tognoni G., et al. n–3 Fatty acids in patients with multiple cardiovascular risk factors (Risk and Prevention Study) N. Engl. J. Med. 2013;368:1800–1808. doi: 10.1056/NEJMoa1205409.
    1. Calder P.C., Yaqoob P. Marine omega-3 fatty acids and coronary heart disease. Curr. Opin. Cardiol. 2012;27:412–419. doi: 10.1097/HCO.0b013e328353febd.
    1. Calder P.C. Limited impact of omega-3 fatty acids in patients with multiple cardiovascular risk factors. Evid. Based Med. 2014;19:18. doi: 10.1136/eb-2013-101440.
    1. Kotwal S., Jun M., Sullivan D., Perkovic V., Neal B. Omega 3 fatty acids and cardiovascular outcomes: Systematic review and meta-analysis. Circ. Cardiovasc. Qual. Outcomes. 2012;5:808–818. doi: 10.1161/CIRCOUTCOMES.112.966168.
    1. Kwak S.M., Myung S.K., Lee Y.J., Seo H.G. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: A meta-analysis of randomized, double-blind, placebo-controlled trials. Arch. Intern. Med. 2012;172:686–694. doi: 10.1001/archinternmed.2012.262.
    1. Trikalinos T., Lee J., Moorthy D., Yu W., Lau J., Lichtenstein A., Chung M. Effects of eicosapentanoic acid and docosahexanoic acid on mortality across diverse settings: Systematic review and meta-analysis of randomized trials and prospective cohorts. Tech. Rev. 2012;17:4.
    1. Rizos E., Ntzani E., Bika E., Kostapanos M., Elisaf M. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: A systematic review and meta-analysis. JAMA. 2012;308:1024–1033. doi: 10.1001/2012.jama.11374.
    1. Casula M., Soranna D., Catapano A.L., Corrao G. Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized, double blind, placebo controlled trials. Atheroscler. Suppl. 2013;14:243–251. doi: 10.1016/S1567-5688(13)70005-9.
    1. Wen Y.T., Dai J.H., Gao Q. Effects of omega-3 fatty acid on major cardiovascular events and mortality in patients with coronary heart disease: A meta-analysis of randomized controlled trials. Nutr. Metab. Cardiovasc. Dis. 2014;24:470–475. doi: 10.1016/j.numecd.2013.12.004.
    1. Maki K.C., Palacios O.M., Bell M., Toth P.P. Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: An updated meta-analysis and review of research gaps. J. Clin. Lipidol. 2017;11:1152–1160.e2. doi: 10.1016/j.jacl.2017.07.010.
    1. Aung T., Halsey J., Kromhout D., Gerstein H.C., Marchioli R., Tavazzi L., Geleijnse J.M., Rauch B., Ness A., Galan P., et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks. JAMA Cardiol. 2018;3:225–234. doi: 10.1001/jamacardio.2017.5205.
    1. Abdelhamid A., Brown T., Brainard J., Biswas P., Thorpe G., Moore H., Deane K., AlAbdulghafoor F., Summerbell C., Worthington H., et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst. Rev. 2018:CD003177. doi: 10.1002/14651858.CD003177.pub4.
    1. Bhatt D.L., Steg P.G., Miller M., Brinton E.A., Jacobson T.A., Ketchum S.B., Doyle R.T., Juliano R.A., Jiao L., Granowitz C., et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N. Engl. J. Med. 2019;380:11–22. doi: 10.1056/NEJMoa1812792.
    1. Hu Y., Hu F.B., Manson J.E. Marine omega-3 supplementation and cardiovascular disease: An updated meta-analysis of 13 randomized controlled trials involving 127,477 participants. J. Am. Heart Assoc. 2019;8:e013543. doi: 10.1161/JAHA.119.013543.
    1. Einvik G., Ole Klemsdal T., Sandvik L., Hjerkinn E.M. A randomized clinical trial on n-3 polyunsaturated fatty acids supplementation and all-cause mortality in elderly men at high cardiovascular risk. Eur. J. Cardiovasc. Prev. Rehabil. 2010;17:588–592. doi: 10.1097/HJR.0b013e328339cc70.
    1. Rimm E.B., Appel L.J., Chiuve S.E., Djoussé L., Engler M.B., Kris-Etherton P.M., Mozaffarian D., Siscovick D.S., Lichtenstein A.H. Seafood long-chain n-3 polyunsaturated fatty acids and cardiovascular disease: A science advisory from the American Heart Association. Circulation. 2018;138:35–47. doi: 10.1161/CIR.0000000000000574.
    1. Skulas-Ray A.C., Wilson P.W.F., Harris W.S., Brinton E.A., Kris-Etherton P.M., Richter C.K., Jacobson T.A., Engler M.B., Miller M., Robinson J.G., et al. Omega-3 fatty acids for the management of hypertriglyceridemia: A science advisory from the American Heart Association. Circulation. 2019;140:e673–e691. doi: 10.1161/CIR.0000000000000709.
    1. Mach F., Baigent C., Carapano A.L., Koskinas K.C., Casula M., Badimon L., Chapman M.J., de Backer G.G., Delgado V., Ference B.A., et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur. Heart J. 2020;41:111–188. doi: 10.1093/eurheartj/ehz455.
    1. The Living Standards of Medical Care in Diabetes—Updates to the standards of medical care in diabetes. [(accessed on 7 February 2020)]; Available online: .
    1. Orringer C.E., Jacobson T.A., Maki K.C. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. J. Clin. Lipidol. 2019;13:860–872. doi: 10.1016/j.jacl.2019.10.014.
    1. Kris-Etherton P.M., Harris W.S., Appel L.J. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106:2747–2757. doi: 10.1161/01.CIR.0000038493.65177.94.
    1. Siscovick D.S., Barringer T.A., Fretts A.M., Wu J.H.Y., Lichtenstein A.H., Costello R.B., Kris-Etherton P.M., Jacobson T.A., Engler M.B., Alger H.M., et al. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: A Science Advisory from the American Heart Association. Circulation. 2017;135:e867–e884. doi: 10.1161/CIR.0000000000000482.
    1. NICE Cardiovascular disease: Risk assessment and reduction, including lipid modification (clinical guideline CG181) [(accessed on 14 July 2014)]; Available online: .
    1. Von Schacky C. Omega-3 fatty acids in cardiovascular disease—An uphill battle. Prostagland. Leukot. Essent Fatty Acids. 2015;92:41–47. doi: 10.1016/j.plefa.2014.05.004.
    1. Rice H.B., Bernasconi A., Maki K.C., Harris W.S., von Schacky C., Calder P.C. Conducting omega-3 clinical trials with cardiovascular outcomes: Proceedings of a Workshop held at ISSFAL 2014. Prostagland. Leukot. Essent. Fatty Acids. 2016;107:30–42. doi: 10.1016/j.plefa.2016.01.003.
    1. Schuchardt J.P., Hahn A. Bioavailability of long-chain omega-3 fatty acids. Prostagland. Leukot. Essent. Fatty Acids. 2013;89:1–9. doi: 10.1016/j.plefa.2013.03.010.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe